Prognose

Das durchschnittliche Kursziel der Analysten beträgt +3,43€(+512,50%). Der Median liegt bei +3,43€(+512,50%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

23andMe wants to sell its most valuable asset. Will your DNA data be safe?
The bankruptcy of 23andMe Holding Co. has thrust the issue of data privacy firmly into the spotlight as the DNA testing company looks to sell its most valuable asset: a vast trove of customers' genetic data.» Mehr auf marketwatch.com
With 23andMe filing for bankruptcy, what happens to consumers' genetic data?
The announcement that 23andMe is filing for bankruptcy and has put its genetic genealogy database up for sale has sent its customers into a bit of a privacy tizzy. On March 21, California Attorney General Bob Bonta issued a consumer alert with detailed instructions about how to delete one's data.» Mehr auf techxplore.com
23andMe shares jump as US judge allows sale of customer data
23andMe (NASDAQ:ME) shares rebounded more than 60% on Thursday after a US judge confirmed the genetic testing company is allowed to sell customer data as part of its Chapter 11 bankruptcy proceedings. This data, including medical and ancestry-related information from more than 15 million customers, is considered one of the company's most valuable assets.» Mehr auf proactiveinvestors.com

Im letzten Quartal hatte 23ANDME HLDG A DL -,0001 Aktie einen Umsatz von 57,91 Mio€ und ein Nettoeinkommen von −43,76 Mio€